Aim
To describe antiviral prescription patterns and patient characteristics associated with antiviral receipt after zoster diagnosis.
design and setting
Descriptive study and risk factor analysis using electronic healthcare records from UK general practice.
Method
Incident adult zoster cases occurring between 2000 and 2011 were identified in the General Practice Research Database. Therapy records were searched for antiviral prescriptions of aciclovir, famciclovir, or valaciclovir within 7 days of zoster diagnosis. The proportion of incident zoster cases receiving antivirals was calculated and multivariable logistic regression used to assess associations between patient characteristics and antiviral use.
results
Of 142 216 incident zoster cases 58.1% received an antiviral prescription. The majority (69.0%) were aciclovir. The proportion receiving antiviral prescriptions increased with age up to 65 years, then declined to 56.8% among patients aged ≥85 years. Being female and of higher socioeconomic status were associated with higher antiviral receipt. Antivirals were more commonly prescribed to immunosuppressed patients with herpes zoster (odds ratio 1.27; 95% CI = 1.22 to 1.33), however they were not given routinely to this patient group.
conclusion
Antiviral therapies for zoster are underprescribed in UK general practice even among groups, such as immunosuppressed and older individuals, for whom guidelines recommend treatment. Patients may present too late to receive treatment or physicians may decide that antivirals are not essential treatment. Consideration could be given to reviewing the guidelines.
in GPRD during the study period, without any consultations for zoster during the previous year. For patients with recurrent zoster episodes during the study period only the first episode was included. Those with zoster episodes occurring within 1 year of the start date were excluded, to remove potentially incorrectly dated prevalent cases. 9 Patients diagnosed with zoster encephalitis, zoster meningitis, or with another central nervous system complication within 7 days of the first zoster record were also excluded (n = 113) as they would typically be treated in secondary care. Read Codes indicating the anatomical site of zoster were searched for in all records within a zoster episode, defined as 1 year following first zoster record. Site of zoster was categorised into ophthalmic, other non-truncal and unspecified site; there is no existing Read Code for truncal zoster.
Sociodemographic characteristics of zoster cases
Age, sex, and geographical health region were obtained from the extracted GPRD data. Age was categorised as 18-49, 50-64, 65-74, 75-84, or ≥85 years. Socioeconomic status was analysed using quintiles of the Index of Multiple Deprivation (IMD) score, available for patients registered at English practices agreeing to link medical records with other databases. The patient's home postcode is mapped at the lower level super output level to the corresponding 2007 IMD score; a low quintile represents the least deprived. As patient-level IMD score was not available for patients from unlinked practices in England, a sensitivity analysis was run using practicelevel IMD quintile when patient-level IMD quintile was unavailable. 10 Identifying comorbidities at zoster diagnosis As NHS guidelines recommend antiviral prescription for all immunosuppressed individuals, prescribing patterns were explored in this group. Patients were considered severely immunosuppressed if they had a diagnosis within 2 years preceding their zoster episode of leukaemia, lymphoma, or a bone marrow transplant or if they had ever had a diagnosis of HIV, a splenectomy, an organ/tissue transplant, myeloma diagnosis, or 'other immune deficiencies' (for example, immunodeficiency with predominantly antibody defects such as selective IgA immune deficiency and agammaglobulinemia, aplastic anaemias, and non-specific diagnoses of immune disorder). Patients prescribed at least one immunosuppressive medication, including oral corticosteroids, ≤3 months before their zoster episode were also considered severely immunosuppressed.
To explore antiviral prescribing patterns among patients with moderate immunosuppression, the following autoimmune conditions were flagged: diabetes, rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.
Antiviral use
Antiviral prescriptions including aciclovir, famciclovir, or valaciclovir within 7 days of a zoster diagnosis were identified from GPRD therapy records.
Data analysis
Data were analysed using STATA/MP (version 11.2). The proportion of incident zoster cases receiving antivirals was determined, and described by various patient characteristics. The association between antiviral use and patient characteristics was assessed using multivariable logistic regression adjusting for age, sex, region, year, zoster site, and immunosuppression status. Socioeconomic status was not adjusted for as it was only available for selected English practices.
reSuLtS
Between 2000 and 2011 142 216 incident zoster cases were identified. Of these 82 656 (58.1%) received an antiviral prescription within 7 days of diagnosis in GPRD. Of those prescribed antivirals 80 751 (97.7%) were given on the day of the zoster diagnosis. The most commonly prescribed antiviral was aciclovir (69.0%), followed by famciclovir (27.8%) and valaciclovir (3.5%). A small number (n = 224) of cases had two different antivirals prescribed on the same day and were included in both antiviral groups (therefore totals do not add up to 100%).
The proportion of patients prescribed antivirals increased with age up to
how this fits in
This article is the first to describe who receives antiviral therapy following a zoster diagnosis within the UK. It highlights that antivirals are under-prescribed in UK primary care, including among those particularly recommended for treatment, such as older individuals and those with immunosuppressive conditions. Although patients may present too late to receive therapy, under-treatment may reflect poor adherence to treatment guidelines. Consideration could be given to reviewing the guidelines.
65-74 years, when the percentage plateaued and then reduced to 56.8% among patients aged ≥85 years (Table 1) . Females were more likely to be prescribed antivirals compared to males (adjusted odds ratio
[AOR] 1.11, 95% confidence interval [CI] = 1.09 to 1.13). However, the sex difference disappeared among patients aged ≥75 years ( Figure 1 ) (in c 2 tests P>0.2). Patients with an ophthalmic zoster diagnosis were less likely to receive antivirals compared to patients with zoster at an unspecified site (AOR 0.66, 95% CI = 0.61 to 0.72) ( Table 1) . Similarly, patients with other non-truncal zoster were less likely to be prescribed antivirals (AOR 0.34, 95% CI = 0.30 to 0.40) ( Table 1 Zoster patients with immunosuppression were 27% more likely to receive antivirals compared to patients without immunosuppression (AOR 1.27, 95% CI = 1.22 to 1.33) ( Table 2) . Some evidence for greater antiviral use was found for all patients with severe immunosuppression, excluding myeloma (AOR 1.03, 95% CI = 0.85 to 1.24) ( Table 2) .
Of the selected autoimmune conditions considered to cause moderate immunosuppression, there was strong evidence that patients with rheumatoid arthritis were more likely to receive antiviral therapy, compared to patients without rheumatoid arthritis (Table 2 ). This effect was seen both among rheumatoid arthritis patients not taking immunosuppressive therapies (AOR 1.17, 95% CI = 1.05 to 1.29), and among rheumatoid arthritis patients on immunosuppressive therapy (AOR 1.28, 95% CI = 1.14 to 1.42). A similar pattern was seen among systemic lupus erythematosus patients ( (Table 2) .
dIScuSSIon

Summary
In the UK between 2000 and 2011, the overall proportion of patients prescribed antivirals within 7 days of a zoster diagnosis was low (58.1%) though a clear increase was seen over time. Aciclovir was the most common antiviral prescribed. Antiviral prescriptions increased with age; however this trend stopped after age 65 years and prescriptions declined among patients ≥85 years. Being female, of higher socioeconomic status, and registered at a GP in Northern Ireland or Scotland was associated with higher antiviral receipt. Although antivirals were more commonly prescribed to immunosuppressed patients with herpes zoster, they were not given routinely in general practice to this patient group.
Why are antiviral prescriptions for zoster low? The finding that a low proportion of patients are prescribed antivirals for an acute episode of zoster correlates with a previous study of GPRD data reporting that 56.3% of 27 225 immunocompetent patients with herpes zoster aged ≥50 years received antivirals between 2000 and 2006. 3 These findings could suggest a lack of adherence to guidelines. Antivirals are generally safe, well tolerated, 4 and aciclovir is inexpensive, therefore neither adverse effects nor cost implications can explain their low use following zoster diagnosis. It is possible that antivirals are not seen as essential treatment, as they do not provide a cure, rather they can reduce duration of the rash and the severity of pain during the episode. Although antivirals are suggested to reduce the risk of post-herpetic neuralgia, evidence is inconclusive, [5] [6] [7] which may again deter physicians from prescribing them. This may be especially pertinent to mild cases of zoster.
An alternative explanation is patients are presenting too late to receive treatment; more than 72 hours after rash onset. This 72-hour cut-off reflects an arbitrary criterion used in clinical trials of antiviral therapy in patients with herpes zoster. 4 This may be an unrealistic time frame for patients to secure an appointment with their GP. 4 Therefore guidelines encourage GPs to 'consider' use of antivirals within 7 days of rash onset for older or immunosuppressed patients. The guidelines for treating patients presenting after 72 hours from rash onset lack clarity, and furthermore, are based on limited evidence [11] [12] both of which may deter prescribing.
Patients may also present following the 7-day window when it is too late to receive antiviral therapy. Although data on time from actual rash onset to presentation to the GP is not available in this data set, two previous UK studies suggest patients present soon after rash onset: Scott et al reported that 50-60% of patients aged >50 years presented to GPs within 72 hours of rash onset, 13 and analyses of data from Thomas et al shows that 65% of adult patients with herpes zoster presented by 72 hours, with less than 7% presenting after 7 days. 14 Additionally, a small proportion of immunosuppressed patients who get disseminated zoster will be referred, as per guidelines, to secondary care for systemic therapy and their antiviral use not recorded here. However this would not explain the low prescribing rates for the majority of patients in this study.
Why are there age, sex, regional, and socioeconomic differences? As expected the proportion of patients with herpes zoster prescribed antivirals increases with age. Explanations for why this trend plateaus at age 65 years and subsequently declines among the oldest may include; older patients being in nursing homes and presenting to GPs later, or reluctance to prescribe to older patients nearing the end of their life. Patients in Scotland and Northern Ireland were more often treated with antivirals, which may likely as the zoster site was seldom recorded. Despite this, it is surprising that less than 50% of cases with a definite diagnosis of ophthalmic or other non-truncal zoster received antivirals.
